Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Aerie Pharmaceuticals Receives Early Notification Of FDA Acceptance Of NDA Submission For Roclatan

By Aerie Pharmaceuticals, Inc. | July 24, 2018

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today reported that it has received the “Day 74” notification from the FDA earlier than scheduled, the FDA has completed its initial 60-day review of the NDA (new drug application) for Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02 percent/0.005 percent and the FDA has determined that the application is sufficiently complete to permit a substantive review.

The PDUFA (Prescription Drug User Fee Act) goal date for the completion of the FDA’s review of the Roclatan NDA is set for March 14, 2019. This date reflects a standard 10-month review period and is consistent with management’s expectations for the 505(b)(2) filing. The “Day 74” notification indicated that the FDA has not identified any potential review issues, and did not mention the need for an advisory committee.

“We are delighted with this positive news on our Roclatan NDA, and, if approved, we expect to be fully prepared to launch Roclatan using our existing sales force, which is already making excellent progress in the early months of our Rhopressa launch,” said Vicente Anido, Jr., Ph.D., chairman and CEO at Aerie.

Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02 percent/0.005 percent, is a once-daily eye drop designed to reduce intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. It is a fixed dose combination of Aerie’s Rhopressa (netarsudil ophthalmic solution) 0.02 percent, which is currently available in the United States, and widely-prescribed PGA (prostaglandin analog) latanoprost. Roclatan successfully achieved its primary efficacy endpoint in two Phase 3 registration trials, named Mercury 1 and Mercury 2, and also achieved successful 12-month safety and efficacy results in Mercury 1.

Aerie submitted the Roclatan New Drug Application (NDA) with the FDA in May 2018 and, in July 2018, the FDA set the PDUFA (Prescription Drug User Fee Act) goal date for the completion of the FDA’s review of the Roclatan NDA for March 14, 2019. A third Phase 3 trial for Roclatan, named Mercury 3, is currently underway in Europe but is not required for approval in the United States.

(Source: Aerie Pharmaceuticals, Inc.)


Filed Under: Drug Discovery

 

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE